Janssen Pharmaceutical Unlimited Company Sustainability Profile
Janssen Pharmaceutical Unlimited Company, a subsidiary of Johnson & Johnson, is a leading player in the global pharmaceutical industry, headquartered in Ireland (IE). Founded in 1953, the company has established a strong presence in key operational regions, including Europe, North America, and Asia, focusing on innovative solutions across various therapeutic areas such as oncology, immunology, and neuroscience. Renowned for its commitment to research and development, Janssen offers a diverse portfolio of core products, including groundbreaking treatments that address unmet medical needs. The company has achieved notable milestones, including the development of several blockbuster drugs that have significantly impacted patient care. With a strong market position, Janssen continues to be recognised for its contributions to healthcare, driving advancements that enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Janssen Pharmaceutical Unlimited Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Janssen Pharmaceutical Unlimited Company's score of 78 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Janssen Pharmaceutical Unlimited Company, headquartered in Ireland (IE), currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Johnson & Johnson, any emissions data or climate commitments would be inherited from its parent company. Johnson & Johnson has established various climate initiatives, including Science-Based Targets Initiative (SBTi) commitments, which aim to significantly reduce greenhouse gas emissions across its operations. However, specific reduction targets or achievements for Janssen Pharmaceutical are not detailed in the available information. The company is part of a broader corporate family that is actively engaged in sustainability efforts, including commitments to renewable energy and emissions reduction strategies. These initiatives are cascaded from Johnson & Johnson, which is known for its comprehensive approach to addressing climate change and reducing its carbon footprint. In summary, while Janssen Pharmaceutical Unlimited Company does not provide specific emissions data or reduction targets, it aligns with the climate commitments and initiatives set forth by its parent organization, Johnson & Johnson.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Janssen Pharmaceutical Unlimited Company's Industry?
How Carbon Intensive is Janssen Pharmaceutical Unlimited Company's Location?
Janssen Pharmaceutical Unlimited Company's Scope 3 Categories Breakdown
Janssen Pharmaceutical Unlimited Company's Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Janssen Pharmaceutical Unlimited Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Janssen Pharmaceutical Unlimited Company has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
